Stalicla raises CHF 2M for neurodevelopmental drug programs

09.07.2025 16:18, Rita Longobardi

Geneva-based biotech company Stalicla has secured CHF 2M in financing to support the development of its precision medicine programs for neurodevelopmental and neuropsychiatric conditions.

The new funds will help sustain operations and advance key programs as the company prepares for its Series C financing and potential strategic partnerships. The round, backed by Addex Therapeutics, reflects continued investor confidence in Stalicla's platform for identifying biologically distinct subgroups of patients—an approach the company calls DEPI (Databased Endophenotyping Precision Identification)—and its lead autism programs, STP1 and STP2.

Stalicla is also working on STP7, a potential treatment targeting a brain receptor involved in conditions such as Fragile X syndrome and addiction. The candidate, known as mavoglurant, recently completed a study to evaluate how it interacts with other drugs, a key step before late-stage clinical trials. Further development is ongoing in partnership with the U.S. National Institute on Drug Abuse.

Stalicla was ranked among the TOP 100 Swiss Startups in 2022.


Stalicla's team (from up left to down right): Eric Painbeni (Head of Clinical Operations), Laurent Forestier (CFO), Jean-Marc Hyvelin (Head of Operations), Lynn Durham (CEO and Founder), Atul Mahableshwarkar (Chief Medical Officer), Laura Perez-Cano (Head of Discovery), and Emre Guney (CTO)